PIK3CA and breast carcinoma: The safety and efficacy of alpelisib in combination with fulvestrant were evaluated in the phase 3 SOLAR-1 trial of patients with PIK3CA-mutated, hormone receptor-positive (HR+), HER2– advanced breast cancer who had received prior endocrine therapy.